Unlocking the Immune System to Attack Cancer    


Neon Therapeutics (NASDAQ: NTGN) is a clinical-stage immuno-oncology company leading in the field of neoantigen-targeted therapies and dedicated to transforming the treatment of each patient’s cancer by directing the immune system towards neoantigens. We have pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies using two distinct approaches. In NEON / ONE, these neoantigens are specific to each individual. In NEON / SELECT, these neoantigens are shared across subsets of patients and tumor types. Our most advanced product candidate is NEO‑PV‑01, a personal neoantigen vaccine, that is currently being evaluated in a Phase 1b open‑label clinical trial for patients with metastatic melanoma, non‑small cell lung cancer or bladder cancer.


Year Invested: 2015
Location: Cambridge, Mass.
Visit: neontherapeutics.com

Recent News

September 6, 2018
Neon Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference

August 21, 2018
Neon Therapeutics Appoints Jolie M. Siegel as General Counsel

August 6, 2018
Neon Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Highlights

Read More News

Associated Team Members

Robert Kamen, Ph.D.
Venture Partner

Cary Pfeffer, M.D.
Partner

Robert Tepper, M.D.
Partner

Stephen Sherwin, M.D.
Venture Partner

Ton Schumacher, Ph.D.
Venture Partner